Specialising in the field of Oncology, we provide the Australian and New Zealand medical community with access to the most advanced genetic testing facilities available to enable medical practitioners to design accurate and reliable targeted therapies for their patients’ individual diseases.
Until recently, it has been impossible to predict precisely how two people with the same type of cancer will respond to treatment. Through the analysis of Circulating Tumour Cells (CTCs) in a simple blood test, it is now possible to provide health practitioners with information to help overcome this challenge.
We are proud to be bringing the future of personalised cancer testing to patients, today.
Healthcare practitioners are welcome to contact Medical Director Dr. Joachim Fluhrer to discuss the clinical utility of liquid biopsy on a case by case basis.